Skip to content

At ACADIA, we are committed to bringing new therapies to patients living with debilitating central nervous system disorders.

About Us

ACADIA Pharmaceuticals is a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders.
More »


News

August 09, 2010
ACADIA Pharmaceuticals Reports Second Quarter 2010 Financial Results

August 02, 2010
ACADIA Pharmaceuticals to Announce Second Quarter 2010 Financial Results on August 9, 2010

More News »

Product Candidates

We are developing a portfolio of four product candidates. Our most advanced product candidate is pimavanserin, which is being developed in collaboration with Biovail for three separate neurological and psychiatric indications, including a Phase III program for Parkinson's disease psychosis. In addition, we have a product candidate in
Phase II for chronic pain, a product candidate in Phase I for glaucoma, and a program in IND-track development for schizophrenia.      More »


Company Information

Investor's Kit Request Information »
Investor Webcasts Investor Webcasts »
Email Updates Email Updates »